End-of-life distressCluster 10 · Outcomes · Full-dose research · separate evidence

Psilocybin, end-of-life distress, and microdosing

Research on serious-illness distress has primarily used one or more supervised perceptible doses with psychological support. It does not establish repeated low-dose microdosing as an end-of-life treatment.

90-second quick read · deeper research available

Need the full research version?

This is the 90-second quick-reference version on imicrodosing.net. For the cited deep dive, continue to the full .org research page.

Read the full .org research companion →Browse related 90-second reads →

Safety-sensitive topic

Research first, not a treatment promise.

This page separates microdosing evidence from full-dose clinical research and does not recommend changing medication or care.

MixedControlled evidence
SeparateFull-dose research
VariableIndividual response
NoneUniversal protocol

Evidence in brief

Psilocybin, end-of-life distress, and microdosing

Research on serious-illness distress has primarily used one or more supervised perceptible doses with psychological support. It does not establish repeated low-dose microdosing as an end-of-life treatment.

What to hold onto

Three boundaries that prevent overclaiming

Common questions

Answered directly

Is microdosing proven to treat this condition?
No. The condition-specific microdosing evidence is not strong enough to establish treatment effectiveness.

Do full-dose psilocybin trials answer the question?
No. Dose, setting, screening, psychological support, and product standardization are different.

What should someone on medication do?
Do not stop, taper, or combine prescribed medication based on a website. Use a qualified prescriber or pharmacist.

Product-format context

Product descriptions, laboratory documentation, fulfillment policies, and client support remain on iMicrodosing.com. Deeper research remains on iMicrodosing.org.

Educational information only. Not medical advice. 21+ only.